Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.

A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients with OUD and AUD, offering potential new treatments for addiction.

A study suggests that weight loss medications like Ozempic may help reduce the risk of overdose and alcohol intoxication in people with substance use disorders.

The large study analyzed more 500,000 people with a history of opioid use disorder and more than 800,000 with alcohol use disorder. Results show that those who took Ozempic or a similar GLP-1 receptor agonist drug (which are approved to treat conditions such as type 2 diabetes or obesity) had a 40 percent lower chance of overdosing on opioids and a 50 percent lower risk of getting drunk compared to those who didn't take the medication.

In a huge new statistical analysis, researchers have found more evidence than ever that drugs like Ozempic can help curb alcohol and opioid addiction. Published in the journal Addiction, this new study saw researchers from Loyola University Chicago sift through more than 1.